Actinogen Medical Enrolls Final Patient For Alzheimer’s Treatment Trial

Clinical-stage biotech company Actinogen Medical Limited (ASX: ACW) today announced the registration of final patient into its phase two study of Xanamem called XanADu.

XanADu is a phase two placebo-controlled study aimed to evaluate the tolerability, efficacy and safety of Xanamem in the treatment of patients who have mild Alzheimer. So far, Actinogen Medical has enrolled 186 patients into the study, more than its initial target of 174 patients. It includes the active participation of research site and study teams across Australia, the UK and the USA. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

With this the company gets on track to report its Phase II clinical trial during the second quarter of 2019 as these final patients will reportedly complete the trial in four months from today, i.e. 27 November 2018. This period of four months trial will include the three months treatment with Xanamem or placebo, comparing them in subjects, and one-month observation phase off-treatment. It will then follow a review and collation of data gathered from trial before starting with analysis.

CEO of Actinogen Medical, Dr Bill Ketelbey commented that with the enrollment of final patient, Actinogen has achieved a significant milestone for XanADu as the company now have certainty on the timeline earlier announced for the completion of trial and release of results. He further offered his gratitude to the patients and medical research sites for understanding the cognitive impairment and Alzheimer’s disease and thereby supporting the clinical trial of new drugs that are designed to treat these diseases.

Actinogen management believes that if trial results into positive outcome, it could underscore the substantial step forward in the development of new therapy for the treatment of patients with Alzheimer and other cognitive declines.

On financial performance front, the company has reported a total comprehensive loss of $6,230,609 for the year ended 30 June 2018, almost double from FY17’s loss of $3,190,338. Moreover, cash and cash equivalents stood at $10,003,797 as at 30 June 2018, broadly reflecting cash proceeds raised from issue of shares.

The stock of Actinogen Medical Limited (ASX: ACW) last traded at a share price of $0.043 with market capitalization of $47.76 million. Over the past one year the stock has witnessed a negative performance change of 8.51% but this meltdown has increased to 25.86% over the past three months as at 27 November 2018.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report